Great interview as always Strawman.

COO Philip seemed to get a little vague when he was asked specific questions. For example:

i) In relation to the competitor company Icardio with the product Echocardio, whom received FDA approval in the same month as EchoIQ. When asked what this competitor approval meant for EchoIQ, he responded they were about “measurement”. How the two FDA approved software systems differed and why the EIQ product was superior was not well explained.

ii)       When asked the question in relation to progress of the Hydrix (HYD) 3 year agreement signed in April 2023 with EIQ to sell the “Echosolve” software in Australia NZ and Singapore, he was again vague. Philip talked about a pilot being extended out with Hendrix and these things taking time to get moving.  Well, the total operational revenue in FY 24 was only $44,500. This does not speak to a business or relationship that is firing.  In addition, you would think the recent FDA approval might have stirred some interest in the Australian market Philip could expand on.  

iii) Philip was asked about the announced (16/9/24) Icardio.ai collaboration with Abbott to develop artificial intelligence for Abbott’s imaging devices, the response was along the lines of: Well, this does not preclude Abbott from entering an agreement with EIQ. A fair enough statement as far as it goes, but not one that would encourage an investor to open their wallet.

Maybe Philip is not giving too much away because of the competition and the critical stage the company is at.  Fair enough too, and maybe I am being way too harsh.  

It would be great if there is a Strawman Cardio somewhere out there in the medical heartland (note the ingenious word pun), or someone knows one whom can give an objective opinion on EIQ’s software?  Because F*&^%ed if I know what to think.